BeOne Medicines won U.S. accelerated approval for sonrotoclax (Beqalzi) in relapsed or refractory mantle cell lymphoma, adding a new BCL-2 competition point against AbbVie and Roche’s Venclexta in the segment. The FDA action also expands BeOne’s regulatory footprint after its first clearance in China. The approval is particularly notable because it comes as BCL-2 strategies continue to diversify in aggressive hematologic malignancies, and it may create new combination expectations with BTK backbone therapies. BeOne’s regulatory milestone strengthens the company’s ability to pursue further line extensions and combination studies, with payers likely to scrutinize comparative benefit and safety versus existing regimens.